BMC Cancer (Jul 2022)
HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
- Elena Ioana Braicu,
- Catherine Linn Krause,
- Uwe Torsten,
- Herbert Mecke,
- Rolf Richter,
- Lars Hellmeyer,
- Malgorzata Lanowska,
- Bodo Müller,
- Elisa Koch,
- Janine Boenneß-Zaloum,
- Kerstin Ames,
- Radoslav Chekerov,
- Kati Hasenbein,
- Mathias Zimmermann,
- Mandy Mangler,
- Frank Chen,
- Rudolf Tauber,
- Jalid Sehouli
Affiliations
- Elena Ioana Braicu
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- Catherine Linn Krause
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- Uwe Torsten
- Department for Gynecology, Vivantes Klinikum Neukölln
- Herbert Mecke
- Department for Obstetrics and Gynecology, AVK Vivantes
- Rolf Richter
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- Lars Hellmeyer
- Department for Obstetrics and Gynecolgy, Vivantes Klinikum Friedrichshain
- Malgorzata Lanowska
- Department of Gynecology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Charité Mitte
- Bodo Müller
- Department for Gynecology, Vivantes Klinikum Kaulsdorf
- Elisa Koch
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- Janine Boenneß-Zaloum
- Department for Obstetrics and Gynecolgy, Vivantes Klinikum Friedrichshain
- Kerstin Ames
- Department for Gynecology, Vivantes Klinikum Neukölln
- Radoslav Chekerov
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- Kati Hasenbein
- Department for Gynecology, Vivantes Klinikum Humboldthain
- Mathias Zimmermann
- Central Institute of Laboratory Medicine, DRK Kliniken Berlin
- Mandy Mangler
- Department of Gynecology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Charité Mitte
- Frank Chen
- Department for Obstetrics and Gynecology, AVK Vivantes
- Rudolf Tauber
- Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry and Labor Berlin Charité
- Jalid Sehouli
- Department of Gynecology with Center of Oncological Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow Klinikum
- DOI
- https://doi.org/10.1186/s12885-022-09887-5
- Journal volume & issue
-
Vol. 22,
no. 1
pp. 1 – 11
Abstract
Highlights • Serum biomarkers can help to distinguish benign from malignant pelvic masses • We evaluated the diagnostic value of adding HE4, CA125 and ROMA to ultrasound for detecting ovarian cancer • In stage III and IV ovarian cancer all three biomarkers showed excellent performance • ROMA and HE4 performed better than CA125 in the differential diagnosis of ovarian cancer and endometriosis
Keywords
